



MAGNASENSE AND SALIGNOSTICS INITIATE FEASIBILITY STUDY PROJECT

Lund, Sweden and Jerusalem, Israel, 29 August 2024 — Magnasense AB and Salignostics Ltd are pleased to announce the commencement of a feasibility study aimed at exploring potential technology development opportunities. This project will leverage Magnasense's innovative magnetic test strip technology in conjunction with Salignostics' advanced sample collection devices.

This collaborative project between Magnasense AB and Salignostics Ltd is a first step aiming to investigate combining their respective strengths with a focus on accuracy, efficiency, and user-friendliness of diagnostic tests.

Marco Witteveen, CEO of Magnasense AB, commented on the project:

"At Magnasense, we are always looking for ways to push the boundaries of diagnostic technology. This project with Salignostics allows us to explore new frontiers and expand the applications of our magnetic test strip technology. We are excited about the potential this feasibility study holds and look forward to the innovative solutions that may arise."

Dr. Guy Krief, deputy CEO at Salignostics LTD, added:

"This project with Magnasense aligns perfectly with our mission to revolutionize sample collection and diagnostic testing. Combining our expertise in sample collection with Magnasense's magnetic test strip technology opens up potential possibilities for technological advancements. We are eager to see the results of this feasibility study."

The feasibility study is set to commence in Q3 2024, with both companies dedicating resources and expertise to ensure full commitment and will be finalized in Q4 2024

For additional information, please contact:

Marco Witteveen, CEO, Magnasense AB

Email: ir@magnasense.com

The Company's Certified Adviser is Eminova Fondkommission AB | adviser@eminova.se

Salignostics Ltd
JBP Minrav building Floor 4
Hadassah Ein Kerem Medical Center
Jerusalem, Israel
office@salignostics.com



About Salignostics Ltd

Salignostics Ltd is at the forefront of sample collection technology, developing advanced devices that simplify and enhance the process of collecting biological samples. Their solutions are designed to support a wide range of diagnostic applications, contributing to better healthcare outcomes.

About Magnasense AB

Magnasense is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, Magnasense was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Magnasense's website www.magnasense.com.